01 — At a Glance
The Fermentation Factory That Makes TB Drugs Look Profitable
- 52-Week High / Low₹479 / ₹222
- Q3 FY26 Revenue₹43.37 Cr
- Q3 FY26 PAT₹12.46 Cr
- Q3 EPS (₹)₹1.14
- Annualised EPS (Q3×4)₹4.56
- Book Value₹24.3
- Price to Book11.2x
- Dividend Yield0.24%
- Debt / Equity0.27x
- OPM (Q3 FY26)49.1%
Auditor’s Opening Note: Gujarat Themis Biosyn finished Q3 FY26 with ₹43.37 crore revenue (+9.74% YoY), ₹12.46 crore PAT, and a 49.1% operating margin that would make most pharma companies weep into their Ayurvedic supplements. The stock is trading at 62.2x P/E — which is either a sign of explosive future growth, or the market is pricing in the company curing TB with fermentation. Spoiler: it’s neither. It’s just a niche API manufacturer that the Sensex doesn’t know exists yet.
02 — Introduction
When Bacteria Makes Better Profits Than Your Mutual Fund
Let’s talk about Gujarat Themis Biosyn Limited (GTBL). No, not the Bollywood production house. This is the company that makes the boring chemical building blocks for TB and diarrhea medicines. The kind of company that doesn’t appear on NDTV Profit, but appears in your doctor’s prescription notes like clockwork.
Founded in 1981, GTBL is India’s first commercial manufacturer of Rifampicin using fermentation. Rifamycin S and Rifamycin O — two niche pharmaceutical intermediates — are their bread and butter. They’re not glamorous. They’re not trending on Twitter. But they’re profitable, consistent, and the market fundamentally doesn’t understand why. Perfect smallcap bait.
Q3 FY26 delivered exactly what management promised: steady volumes, healthy margins, and zero surprises. Revenue up 9.74% YoY. EBITDA up 12.9%. PAT at ₹12.46 crore. Meanwhile, they’re running an expansion project that would make most companies hyperventilate into a prospectus — doubled fermentation capacity, new API unit live, R&D hitting 3% of revenue, and a hybrid power plant being set up because India’s power grid apparently isn’t cool enough for their fermentation aspirations.
The stock is up 7.89% over a year and the market is still pricing it like Reliance’s secret startup. We’re here to decode the fermentation.
Concall Intelligence (Feb 2026): Dr. Sachin Patel: “This nine-month period had R&D spend of approximately 3% of revenue.” Translation: They’re serious about new products, not just fermentation theatre. The API block validation is done. Export pipelines to US and Europe are active. And nobody’s talking about this company except the TB patients who get their medicine on time.
03 — Business Model: WTF Are Pharmaceutical Intermediates Anyway?
They Make The Raw Materials For Medicines. The Unglamorous Middle Child of Pharma.
Members get full access to every article.
